LONDON- Artificial intelligence and big data are poised to address the complexity of metabolic diseases, drawing out specific genetic and environmental factors that can inform discovery and development of new therapies and providing the means to modify behaviors which underlie those conditions. Read More
G1 Therapeutics Inc. plans to submit a marketing application for the U.S. next year based on FDA feedback from the company's end-of-phase II meeting for trilaciclib, a myelopreservation agent designed to protect bone marrow from damage from chemotherapy. The company expects to expand to Europe afterward. Read More
Vividion Therapeutics Inc. CEO Diego Miralles told BioWorld that $82 million in new series B money will propel research to "clinical proof of concept in at least one of the three lead programs, if not more" as the company – just over a year after sealing a pact worth $101 million up front that brought Celgene Corp. aboard as a collaborator – pulled off an oversubscribed round with its partner on board. Read More
Researchers have discovered that the synaptic protein Bassoon accumulated in the neurons of mice with experimental autoimmune encephalitis, the closest animal model to multiple sclerosis (MS), causing neuronal damage in much the same way that protein aggregates damage neurons in neurodegenerative diseases. Read More
Even as legislation advances in the U.S. Congress to make prescription drugs more affordable for Medicare beneficiaries, lawmakers continue to search for a solution to the problem itself. Read More
DUBLIN – Polyprox Therapeutics Ltd. is the latest contender to enter the promising but increasingly crowded space of harnessing the proteasome for therapeutic effect. The company, a newly launched spinout from the University of Cambridge, is based on more than a decade of research conducted by its founder and chief scientific officer, Laura Itzhaki, who is professor of structural pharmacology at Cambridge and an expert on protein structure, protein folding, protein-protein interactions and protein engineering. Read More
Kerastem Technologies LLC reported that the U.S. FDA accepted its 12-month phase II study and the company plans to begin a phase III study of its cell therapy-based hair regrowth system in early 2020 with an as-yet-unidentified distribution partner. Kerastem is a subsidiary of privately held Bimini Technologies LLC, of Solana Beach, Calif. Read More
Helix Biopharma Corp., of Richmond Hill, Ontario, said it closed a second tranche of a private placement financing for gross proceeds of CA$510,000 (US$379,996). The company is working on completing another private placement tranche by May 17. Helix intends to use the net proceeds for working capital and research and development activities. Read More
Qpex Biopharma Inc., of San Diego, closed a license agreement with Monash University for the worldwide rights to a portfolio of polymyxin antimicrobials for the treatment of highly drug-resistant gram-negative pathogens. Read More
Alimera Sciences Inc., of Atlanta, reported that for the three months ended March 31, consolidated net revenue grew 34% to $12.9 million, compared to $9.6 million during the first quarter last year. U.S. net revenue was approximately $6.8 million during the first quarters of both 2019 and 2018. Read More
